<unk> , sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).<unk>  is a protein kinase inhibitor. The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.<unk>  was approved for medical use in the United States in October 2021. The U.S. Food and Drug Administration (FDA) granted the application for<unk>  priority review, fast track, orphan drug, and breakthrough therapy designations.
Asciminib
Deferasirox
Calcifediol
Deferoxamine
Naloxegol
Deferiprone
Fursultiamine
Morazone